Lukas E. Brümmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lukas E. Brümmer has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Maria Denkinger
Department of Infectious Diseases and Tropical Medicine, University Hospital Heidelberg, Heidelberg, Germany
7 shared publications - Stephan Katzenschlager
Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg, Germany
6 shared publications - Aurélien Macé
FIND
5 shared publications - Christian Erdmann
FH Muenster University of applied sciences
5 shared publications - Nira R. Pollock
Department of Laboratory Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
5 shared publications - Jan Larmann
Faculty of Medicine, RWTH Aachen University, 52062 Aachen, Germany
4 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 94
Population health and implementation outcomes of self-testing for SARS-CoV-2 using antigen detecting diagnostics: a systematic review and meta-analysis
- 7 April 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 94
Open AccessPopulation health and implementation outcomes of self-testing for SARS-CoV-2 using antigen detecting diagnostics: a systematic review and meta-analysis
- Open Access
- 27 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-14
Importance of confirmatory test characteristics in optimizing community-based screening for tuberculosis: an epidemiological modeling analysis
Background: The costs, operational barriers, and sensitivity of available tools to confirm a TB diagnosis limit current active case-finding (ACF) efforts for tuberculosis (TB). However, it is not well understood which of these limitations have the greatest epidemiological relevance and might therefore warrant prioritization in confirmatory test development. Methods: To explore which features of the confirmatory testing step most influence the impact of ACF, we developed a state-transition model of a one-time, community-based ACF campaign, with a fixed budget of one million United States dollars for screening and confirmatory testing, assuming an adult target population with four times the national prevalence of Uganda. We compared TB diagnoses, mortality, and transmission when conducting ACF with a currently available confirmatory test (mirroring sputum-based Xpert Ultra) versus ACF with an improved confirmatory test, i.e., (1) increased sensitivity (from 69% to 80%), (2) non-sputum specimen type (increasing specimen availability from 93% to 100%), (3) immediate turn-around of test results at the point-of-care (increasing delivery of positive results from 91% to 100%), or (4) reduced costs (from $20 to $10 per confirmatory test). Results: In a simulated target population of 500,000 adults, 8,029 (1.6%; 95% uncertainty range [UR] 6,634-9,380) had TB disease, and 1,136 (789-1,586) were projected to die of TB in the absence of ACF. Assuming current tests, ACF could reach 149,811 (90,834 − 217,928; 30% of the target population) people under the allotted budget, connecting 1,151 (676-1,813) individuals with TB to treatment and averting 135 (64–249) deaths. Higher diagnostic sensitivity most increased the number of people with TB who received treatment as a result of ACF (by 15% [5–27%]). However, improvements that could benefit individuals regardless of their sputum bacillary load, such as reduced test costs, achieved larger reductions in mortality (11% [4–36%]). Conclusion: Due to greater detection of individuals with high bacillary load, making confirmatory tests for community-based TB screening less expensive and more accessible may lead to greater population health benefits than further increasing test sensitivity. Nonetheless, achieving large (> 20%) increases in the health impact of ACF will require improvements to components of ACF other than the confirmatory diagnostic test.
- 27 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-14
Open AccessImportance of confirmatory test characteristics in optimizing community-based screening for tuberculosis: an epidemiological modeling analysis
Background: The costs, operational barriers, and sensitivity of available tools to confirm a TB diagnosis limit current active case-finding (ACF) efforts for tuberculosis (TB). However, it is not well understood which of these limitations have the greatest epidemiological relevance and might therefore warrant prioritization in confirmatory test development. Methods: To explore which features of the confirmatory testing step most influence the impact of ACF, we developed a state-transition model of a one-time, community-based ACF campaign, with a fixed budget of one million United States dollars for screening and confirmatory testing, assuming an adult target population with four times the national prevalence of Uganda. We compared TB diagnoses, mortality, and transmission when conducting ACF with a currently available confirmatory test (mirroring sputum-based Xpert Ultra) versus ACF with an improved confirmatory test, i.e., (1) increased sensitivity (from 69% to 80%), (2) non-sputum specimen type (increasing specimen availability from 93% to 100%), (3) immediate turn-around of test results at the point-of-care (increasing delivery of positive results from 91% to 100%), or (4) reduced costs (from $20 to $10 per confirmatory test). Results: In a simulated target population of 500,000 adults, 8,029 (1.6%; 95% uncertainty range [UR] 6,634-9,380) had TB disease, and 1,136 (789-1,586) were projected to die of TB in the absence of ACF. Assuming current tests, ACF could reach 149,811 (90,834 − 217,928; 30% of the target population) people under the allotted budget, connecting 1,151 (676-1,813) individuals with TB to treatment and averting 135 (64–249) deaths. Higher diagnostic sensitivity most increased the number of people with TB who received treatment as a result of ACF (by 15% [5–27%]). However, improvements that could benefit individuals regardless of their sputum bacillary load, such as reduced test costs, achieved larger reductions in mortality (11% [4–36%]). Conclusion: Due to greater detection of individuals with high bacillary load, making confirmatory tests for community-based TB screening less expensive and more accessible may lead to greater population health benefits than further increasing test sensitivity. Nonetheless, achieving large (> 20%) increases in the health impact of ACF will require improvements to components of ACF other than the confirmatory diagnostic test.
- Open Access
Importance of confirmatory test characteristics in optimizing community-based screening for tuberculosis: An epidemiological modeling analysis
Background: Current active case-finding (ACF) efforts for tuberculosis (TB) are limited by the costs, operational barriers, and sensitivity of available tools to confirm a TB diagnosis. However, it is not well understood which of these limitations has the greatest epidemiological relevance and might therefore warrant prioritization in test development. Methods: We developed a state-transition model of a one-time, community-based ACF intervention, with a fixed budget of one million United States dollars for screening and confirmatory testing. Assuming an adult population with four time the national prevalence of Uganda, we compared the impact of this intervention on TB diagnoses, mortality, and transmission when using a currently available confirmatory test (mirroring sputum-based Xpert Ultra) versus an improved confirmatory test. We considered the following test improvements: (1) increased sensitivity (from 69% to 80%), (2) non-sputum specimen type (increasing specimen availability from 93% to 100%), (3) immediate turn-around of test results (increasing delivery of positive results from 91% to 100%), (4) reduced costs (from $20 to $9 per confirmatory test). For those individuals not included in ACF efforts, TB outcomes under routine care were informed by recent natural history models. Results: In a simulated target population of 400,000 adults, 6,421 (1.6%; 95% uncertainty range [UR] 5,316-7,531) had TB disease, and 873 (612-1,182) were projected to die of TB in the absence of ACF. Assuming current tests, ACF efforts could reach 83,808 (59,388-118,601; 21% of the target population) people under the allotted budget, connecting 651 (429-983) individuals with TB to treatment and averting 76 (39-132) deaths. Of all hypothetical confirmatory test improvements modeled, higher diagnostic sensitivity most increased the number of people with TB who received treatment as a result of ACF (by 14% [4-26%]). However, considering mortality or transmission as a metric, the largest reductions resulted from tests that provided immediate turn-around of results (by 11% [5-18%]). Conclusion: Making confirmatory tests for community-based TB screening more accessible and rapid may lead to greater population health benefits than further increasing sensitivity. Nonetheless, achieving large (>20%) increases in the health impact of ACF will require improvements to components of ACF other than the confirmatory diagnostic test.
Open AccessImportance of confirmatory test characteristics in optimizing community-based screening for tuberculosis: An epidemiological modeling analysis
Background: Current active case-finding (ACF) efforts for tuberculosis (TB) are limited by the costs, operational barriers, and sensitivity of available tools to confirm a TB diagnosis. However, it is not well understood which of these limitations has the greatest epidemiological relevance and might therefore warrant prioritization in test development. Methods: We developed a state-transition model of a one-time, community-based ACF intervention, with a fixed budget of one million United States dollars for screening and confirmatory testing. Assuming an adult population with four time the national prevalence of Uganda, we compared the impact of this intervention on TB diagnoses, mortality, and transmission when using a currently available confirmatory test (mirroring sputum-based Xpert Ultra) versus an improved confirmatory test. We considered the following test improvements: (1) increased sensitivity (from 69% to 80%), (2) non-sputum specimen type (increasing specimen availability from 93% to 100%), (3) immediate turn-around of test results (increasing delivery of positive results from 91% to 100%), (4) reduced costs (from $20 to $9 per confirmatory test). For those individuals not included in ACF efforts, TB outcomes under routine care were informed by recent natural history models. Results: In a simulated target population of 400,000 adults, 6,421 (1.6%; 95% uncertainty range [UR] 5,316-7,531) had TB disease, and 873 (612-1,182) were projected to die of TB in the absence of ACF. Assuming current tests, ACF efforts could reach 83,808 (59,388-118,601; 21% of the target population) people under the allotted budget, connecting 651 (429-983) individuals with TB to treatment and averting 76 (39-132) deaths. Of all hypothetical confirmatory test improvements modeled, higher diagnostic sensitivity most increased the number of people with TB who received treatment as a result of ACF (by 14% [4-26%]). However, considering mortality or transmission as a metric, the largest reductions resulted from tests that provided immediate turn-around of results (by 11% [5-18%]). Conclusion: Making confirmatory tests for community-based TB screening more accessible and rapid may lead to greater population health benefits than further increasing sensitivity. Nonetheless, achieving large (>20%) increases in the health impact of ACF will require improvements to components of ACF other than the confirmatory diagnostic test.
- Open Access
- 25 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (1) , 154-163
Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis
Introduction: In high-burden settings, low-complexity screening tests for tuberculosis (TB) could expand the reach of community-based case-finding efforts. The potential costs and cost-effectiveness of approaches incorporating these tests are poorly understood. Methods: We developed a microsimulation model assessing 3 approaches to community-based case-finding in hypothetical populations (India-, South Africa-, The Philippines-, Uganda-, and Vietnam-like settings) with TB prevalence 4 times that of national estimates: (1) screening with a point-of-care C-reactive protein (CRP) test, (2) screening with a more sensitive “Hypothetical Screening test” (95% sensitive for Xpert Ultra-positive TB, 70% specificity; equipment/labor costs similar to Xpert Ultra, but using a $2 cartridge) followed by sputum Xpert Ultra if positive, or (3) testing all individuals with sputum Xpert Ultra. Costs are expressed in 2023 US dollars and include treatment costs. Results: Universal Xpert Ultra was estimated to cost a mean $4.0 million (95% uncertainty range: $3.5 to $4.6 million) and avert 3200 (2600 to 3900) TB-related disability-adjusted life years (DALYs) per 100 000 people screened ($670 [The Philippines] to $2000 [Vietnam] per DALY averted). CRP was projected to cost $550 (The Philippines) to $1500 (Vietnam) per DALY averted but with 44% fewer DALYs averted. The Hypothetical Screening test showed minimal benefit compared to universal Xpert Ultra, but if specificity were improved to 95% and per-test cost to $4.5 (all-inclusive), this strategy could cost $390 (The Philippines) to $940 (Vietnam) per DALY averted. Conclusions: Screening tests can meaningfully improve the cost-effectiveness of community-based case-finding for TB but only if they are sensitive, specific, and inexpensive.
- 25 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (1) , 154-163
Open AccessCost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis
Introduction: In high-burden settings, low-complexity screening tests for tuberculosis (TB) could expand the reach of community-based case-finding efforts. The potential costs and cost-effectiveness of approaches incorporating these tests are poorly understood. Methods: We developed a microsimulation model assessing 3 approaches to community-based case-finding in hypothetical populations (India-, South Africa-, The Philippines-, Uganda-, and Vietnam-like settings) with TB prevalence 4 times that of national estimates: (1) screening with a point-of-care C-reactive protein (CRP) test, (2) screening with a more sensitive “Hypothetical Screening test” (95% sensitive for Xpert Ultra-positive TB, 70% specificity; equipment/labor costs similar to Xpert Ultra, but using a $2 cartridge) followed by sputum Xpert Ultra if positive, or (3) testing all individuals with sputum Xpert Ultra. Costs are expressed in 2023 US dollars and include treatment costs. Results: Universal Xpert Ultra was estimated to cost a mean $4.0 million (95% uncertainty range: $3.5 to $4.6 million) and avert 3200 (2600 to 3900) TB-related disability-adjusted life years (DALYs) per 100 000 people screened ($670 [The Philippines] to $2000 [Vietnam] per DALY averted). CRP was projected to cost $550 (The Philippines) to $1500 (Vietnam) per DALY averted but with 44% fewer DALYs averted. The Hypothetical Screening test showed minimal benefit compared to universal Xpert Ultra, but if specificity were improved to 95% and per-test cost to $4.5 (all-inclusive), this strategy could cost $390 (The Philippines) to $940 (Vietnam) per DALY averted. Conclusions: Screening tests can meaningfully improve the cost-effectiveness of community-based case-finding for TB but only if they are sensitive, specific, and inexpensive.
- Open Access
The clinical utility and epidemiological impact of self-testing for SARS-CoV-2 using antigen detecting diagnostics: a systematic review and meta-analysis
Introduction Self-testing for COVID-19 (C19ST) based on antigen detecting diagnostics could significantly support controlling the SARS-CoV-2 pandemic. To inform the World Health Organization in developing a C19ST guideline, we performed a systematic review and meta-analysis of the available literature. Methods We electronically searched Medline and the Web of Science core collection, performed secondary reference screening, and contacted experts for further relevant publications. Any study published between December 1, 2020 and November 30, 2021 assessing the epidemiological impact and clinical utility of C19ST was included. Study quality was evaluated using the Newcastle Ottawa Scale (NOS). The review was registered on PROSPERO (CRD42022299977). Results 11 studies only from high-income countries with an overall low quality (median of 3/9 stars on the NOS) were found. Pooled C19ST positivity was 0.2% (95% CI 0.1% to 0.4%; eight data sets) in populations where otherwise no dedicated testing would have occurred. The impact of self-testing on virus transmission was uncertain. Positive test results mainly resulted in people having to isolate without further confirmation of results (eight data sets). When testing was voluntary by study design, pooled testing uptake was 53.2% (95% CI 36.7% to 68.9%; five data sets. Outside direct health impacts, C19ST reduced quarantine duration and absenteeism from work, and made study participants feel safer. Study participants favored self-testing and were confident that they performed testing and sampling correctly. Conclusions The present data suggests that C19ST could be a valuable tool in reducing the spread of COVID-19, as it can achieve good uptake, may identify additional cases, and was generally perceived as positive by study participants. However, data was very limited and heterogenous, and further research especially in low- and middle-income countries is needed to assess the clinical utility and epidemiological impact of C19ST in more detail. CONTRIBUTIONS TO THE LITERATURE - COVID-19 self-testing (C19ST) using antigen detection could conceivably support pandemic control. A current PubMed search found no systematic evidence synthesis of studies assessing the epidemiological impact and clinical utility of C19ST implementation - We systematically reviewed and meta-analyzed 11 studies including more than 1.1 million persons tested - C19ST can achieve good uptake, may identify additional cases, and was general perceived as positive by study participants, suggesting it to be a valuable tool in reducing the spread of SARS-CoV-2 - Further data especially from low- and middle-income countries is needed to understand the impact of C19ST in more detail
Open AccessThe clinical utility and epidemiological impact of self-testing for SARS-CoV-2 using antigen detecting diagnostics: a systematic review and meta-analysis
Introduction Self-testing for COVID-19 (C19ST) based on antigen detecting diagnostics could significantly support controlling the SARS-CoV-2 pandemic. To inform the World Health Organization in developing a C19ST guideline, we performed a systematic review and meta-analysis of the available literature. Methods We electronically searched Medline and the Web of Science core collection, performed secondary reference screening, and contacted experts for further relevant publications. Any study published between December 1, 2020 and November 30, 2021 assessing the epidemiological impact and clinical utility of C19ST was included. Study quality was evaluated using the Newcastle Ottawa Scale (NOS). The review was registered on PROSPERO (CRD42022299977). Results 11 studies only from high-income countries with an overall low quality (median of 3/9 stars on the NOS) were found. Pooled C19ST positivity was 0.2% (95% CI 0.1% to 0.4%; eight data sets) in populations where otherwise no dedicated testing would have occurred. The impact of self-testing on virus transmission was uncertain. Positive test results mainly resulted in people having to isolate without further confirmation of results (eight data sets). When testing was voluntary by study design, pooled testing uptake was 53.2% (95% CI 36.7% to 68.9%; five data sets. Outside direct health impacts, C19ST reduced quarantine duration and absenteeism from work, and made study participants feel safer. Study participants favored self-testing and were confident that they performed testing and sampling correctly. Conclusions The present data suggests that C19ST could be a valuable tool in reducing the spread of COVID-19, as it can achieve good uptake, may identify additional cases, and was generally perceived as positive by study participants. However, data was very limited and heterogenous, and further research especially in low- and middle-income countries is needed to assess the clinical utility and epidemiological impact of C19ST in more detail. CONTRIBUTIONS TO THE LITERATURE - COVID-19 self-testing (C19ST) using antigen detection could conceivably support pandemic control. A current PubMed search found no systematic evidence synthesis of studies assessing the epidemiological impact and clinical utility of C19ST implementation - We systematically reviewed and meta-analyzed 11 studies including more than 1.1 million persons tested - C19ST can achieve good uptake, may identify additional cases, and was general perceived as positive by study participants, suggesting it to be a valuable tool in reducing the spread of SARS-CoV-2 - Further data especially from low- and middle-income countries is needed to understand the impact of C19ST in more detail
- Open Access
- 26 May 2022
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (5) , e1004011
Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: An updated systematic review and meta-analysis with meta-regression analyzing influencing factors
Background: Comprehensive information about the accuracy of antigen rapid diagnostic tests (Ag-RDTs) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is essential to guide public health decision makers in choosing the best tests and testing policies. In August 2021, we published a systematic review and meta-analysis about the accuracy of Ag-RDTs. We now update this work and analyze the factors influencing test sensitivity in further detail. Methods and findings: We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched preprint and peer-reviewed databases for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 until August 31, 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity with reverse transcription polymerase chain reaction (RT-PCR) testing as a reference. To evaluate factors influencing test sensitivity, we performed 3 different analyses using multivariable mixed-effects meta-regression models. We included 194 studies with 221,878 Ag-RDTs performed. Overall, the pooled estimates of Ag-RDT sensitivity and specificity were 72.0% (95% confidence interval [CI] 69.8 to 74.2) and 98.9% (95% CI 98.6 to 99.1). When manufacturer instructions were followed, sensitivity increased to 76.3% (95% CI 73.7 to 78.7). Sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values (97.9% [95% CI 96.9 to 98.9] and 90.6% [95% CI 88.3 to 93.0] for Ct-values 90%) when high viral loads are present. With viral load, as estimated by Ct-value, being the most influential factor on their sensitivity, they are especially useful to detect persons with high viral load who are most likely to transmit the virus. To further quantify the effects of other factors influencing test sensitivity, standardization of clinical accuracy studies and access to patient level Ct-values and duration of symptoms are needed.
- 26 May 2022
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (5) , e1004011
Open AccessAccuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: An updated systematic review and meta-analysis with meta-regression analyzing influencing factors
Background: Comprehensive information about the accuracy of antigen rapid diagnostic tests (Ag-RDTs) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is essential to guide public health decision makers in choosing the best tests and testing policies. In August 2021, we published a systematic review and meta-analysis about the accuracy of Ag-RDTs. We now update this work and analyze the factors influencing test sensitivity in further detail. Methods and findings: We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched preprint and peer-reviewed databases for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 until August 31, 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity with reverse transcription polymerase chain reaction (RT-PCR) testing as a reference. To evaluate factors influencing test sensitivity, we performed 3 different analyses using multivariable mixed-effects meta-regression models. We included 194 studies with 221,878 Ag-RDTs performed. Overall, the pooled estimates of Ag-RDT sensitivity and specificity were 72.0% (95% confidence interval [CI] 69.8 to 74.2) and 98.9% (95% CI 98.6 to 99.1). When manufacturer instructions were followed, sensitivity increased to 76.3% (95% CI 73.7 to 78.7). Sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values (97.9% [95% CI 96.9 to 98.9] and 90.6% [95% CI 88.3 to 93.0] for Ct-values 90%) when high viral loads are present. With viral load, as estimated by Ct-value, being the most influential factor on their sensitivity, they are especially useful to detect persons with high viral load who are most likely to transmit the virus. To further quantify the effects of other factors influencing test sensitivity, standardization of clinical accuracy studies and access to patient level Ct-values and duration of symptoms are needed.
- Open Access
Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta regression analyzing influencing factors
Background Comprehensive information about the accuracy of antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 is essential to guide public health decision makers in choosing the best tests and testing policies. In August 2021, we published a systematic review and meta-analysis about the accuracy of Ag-RDTs. We now update this work and analyze the factors influencing test sensitivity in further detail. Methods and findings We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 until August 31, 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity with reverse transcription polymerase chain reaction (RT-PCR) testing as a reference. To evaluate factors influencing test sensitivity, we performed 3 different analyses using multivariate mixed-effects meta-regression models. We included 194 studies with 221,878 Ag-RDTs performed. Overall, the pooled estimates of Ag-RDT sensitivity and specificity were 72.0% (95% confidence interval [CI] 69.8 to 74.2) and 98.9% (95% CI 98.6 to 99.1), respectively. When manufacturer instructions were followed, sensitivity increased to 76.4% (95%CI 73.8 to 78.8). Sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values (sensitivity of 97.9% [95% CI 96.9 to 98.9] and 90.6% [95% CI 88.3 to 93.0] for Ct-values <20 and 90%). With viral load, as estimated by Ct-value, being the most influential factor on their sensitivity, they are especially useful to detect persons with high viral load who are most likely to transmit the virus. To further quantify the effects of other factors influencing test sensitivity, standardization of clinical accuracy studies and access to patient level Ct-values and duration of symptoms are needed.
Open AccessAccuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta regression analyzing influencing factors
Background Comprehensive information about the accuracy of antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 is essential to guide public health decision makers in choosing the best tests and testing policies. In August 2021, we published a systematic review and meta-analysis about the accuracy of Ag-RDTs. We now update this work and analyze the factors influencing test sensitivity in further detail. Methods and findings We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 until August 31, 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity with reverse transcription polymerase chain reaction (RT-PCR) testing as a reference. To evaluate factors influencing test sensitivity, we performed 3 different analyses using multivariate mixed-effects meta-regression models. We included 194 studies with 221,878 Ag-RDTs performed. Overall, the pooled estimates of Ag-RDT sensitivity and specificity were 72.0% (95% confidence interval [CI] 69.8 to 74.2) and 98.9% (95% CI 98.6 to 99.1), respectively. When manufacturer instructions were followed, sensitivity increased to 76.4% (95%CI 73.8 to 78.8). Sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values (sensitivity of 97.9% [95% CI 96.9 to 98.9] and 90.6% [95% CI 88.3 to 93.0] for Ct-values <20 and 90%). With viral load, as estimated by Ct-value, being the most influential factor on their sensitivity, they are especially useful to detect persons with high viral load who are most likely to transmit the virus. To further quantify the effects of other factors influencing test sensitivity, standardization of clinical accuracy studies and access to patient level Ct-values and duration of symptoms are needed.
- Top Cited PapersOpen Access
- 12 August 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (8) , e1003735
Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis
Background: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are increasingly being integrated in testing strategies around the world. Studies of the Ag-RDTs have shown variable performance. In this systematic review and meta-analysis, we assessed the clinical accuracy (sensitivity and specificity) of commercially available Ag-RDTs.Methods and findings: We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until 30 April 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcription polymerase chain reaction (RT-PCR) testing. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS-2 assessment tool. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy datasets with 112,323 samples. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity and specificity were 71.2% (95% CI 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively. Sensitivity increased to 76.3% (95% CI 73.1% to 79.2%) if analysis was restricted to studies that followed the Ag-RDT manufacturers’ instructions. LumiraDx showed the highest sensitivity, with 88.2% (95% CI 59.0% to 97.5%). Of instrument-free Ag-RDTs, Standard Q nasal performed best, with 80.2% sensitivity (95% CI 70.3% to 87.4%). Across all Ag-RDTs, sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values, i.e., <20 (96.5%, 95% CI 92.6% to 98.4%) and <25 (95.8%, 95% CI 92.3% to 97.8%), in comparison to those with Ct ≥ 25 (50.7%, 95% CI 35.6% to 65.8%) and ≥30 (20.9%, 95% CI 12.5% to 32.8%). Testing in the first week from symptom onset resulted in substantially higher sensitivity (83.8%, 95% CI 76.3% to 89.2%) compared to testing after 1 week (61.5%, 95% CI 52.2% to 70.0%). The best Ag-RDT sensitivity was found with anterior nasal sampling (75.5%, 95% CI 70.4% to 79.9%), in comparison to other sample types (e.g., nasopharyngeal, 71.6%, 95% CI 68.1% to 74.9%), although CIs were overlapping. Concerns of bias were raised across all datasets, and financial support from the manufacturer was reported in 24.1% of datasets. Our analysis was limited by the included studies’ heterogeneity in design and reporting.Conclusions: In this study we found that Ag-RDTs detect the vast majority of SARS-CoV-2-infected persons within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease, making them a valuable tool to fight the spread of SARS-CoV-2. Standardization in conduct and reporting of clinical accuracy studies would improve comparability and use of data.
- 12 August 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (8) , e1003735
Top Cited PapersOpen AccessAccuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis
Background: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are increasingly being integrated in testing strategies around the world. Studies of the Ag-RDTs have shown variable performance. In this systematic review and meta-analysis, we assessed the clinical accuracy (sensitivity and specificity) of commercially available Ag-RDTs.Methods and findings: We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until 30 April 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcription polymerase chain reaction (RT-PCR) testing. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS-2 assessment tool. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy datasets with 112,323 samples. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity and specificity were 71.2% (95% CI 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively. Sensitivity increased to 76.3% (95% CI 73.1% to 79.2%) if analysis was restricted to studies that followed the Ag-RDT manufacturers’ instructions. LumiraDx showed the highest sensitivity, with 88.2% (95% CI 59.0% to 97.5%). Of instrument-free Ag-RDTs, Standard Q nasal performed best, with 80.2% sensitivity (95% CI 70.3% to 87.4%). Across all Ag-RDTs, sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values, i.e., <20 (96.5%, 95% CI 92.6% to 98.4%) and <25 (95.8%, 95% CI 92.3% to 97.8%), in comparison to those with Ct ≥ 25 (50.7%, 95% CI 35.6% to 65.8%) and ≥30 (20.9%, 95% CI 12.5% to 32.8%). Testing in the first week from symptom onset resulted in substantially higher sensitivity (83.8%, 95% CI 76.3% to 89.2%) compared to testing after 1 week (61.5%, 95% CI 52.2% to 70.0%). The best Ag-RDT sensitivity was found with anterior nasal sampling (75.5%, 95% CI 70.4% to 79.9%), in comparison to other sample types (e.g., nasopharyngeal, 71.6%, 95% CI 68.1% to 74.9%), although CIs were overlapping. Concerns of bias were raised across all datasets, and financial support from the manufacturer was reported in 24.1% of datasets. Our analysis was limited by the included studies’ heterogeneity in design and reporting.Conclusions: In this study we found that Ag-RDTs detect the vast majority of SARS-CoV-2-infected persons within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease, making them a valuable tool to fight the spread of SARS-CoV-2. Standardization in conduct and reporting of clinical accuracy studies would improve comparability and use of data.
- Open Access
The accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis
Background: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are increasingly being integrated in testing strategies around the world. Studies of the Ag-RDTs have shown variable performance. In this systematic review and meta-analysis, we assessed the clinical accuracy (sensitivity and specificity) of commercially available Ag-RDTs. Methods and Results: We registered the review on PROSPERO (Registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix and bioRvix, FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until April 30 th , 2021. Descriptive analyses of all studies were performed and when more than four studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcriptase polymerase chain reaction testing. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS 2 assessment tool. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy data sets with 112,323 samples. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity was 71.2% (95% confidence interval [CI] 68.2 to 74.0) and increased to 76.3% (CI 73.1 to 79.2) if analysis was restricted to studies that followed the Ag-RDT manufacturers’ instructions. The LumiraDx showed the highest sensitivity with 88.2% (CI 59.0 to 97.5). Of instrument-free Ag-RDTs, Standard Q nasal performed best with 80.2% sensitivity (CI 70.3 to 87.4). Across all Ag-RDTs sensitivity was markedly better on samples with lower Ct-values, i.e., th , 2021, we conducted a systematic review and meta-analysis, including a total of 133 clinical and analytical accuracy studies – Across all meta-analyzed studies, when Ag-RDTs were performed according to manufacturers’ recommendations, they showed a sensitivity of 76.3% (CI 73.1 to 79.2), with the LumiraDx (sensitivity 88.2%, CI 59.0 to 97.5) and of the instrument-free Ag-RDT Standard Q (74.9% sensitivity, CI 69.3 to 79.7) performing best. – Across all Ag-RDTs, sensitivity increased to 95.8% (CI 92.3 to 97.8) when restricting the analysis to samples with high viral loads (i.e., a Ct-value <25) and to 83.8% (CI 76.3 to 89.2) when tests were performed on patients within the first week after symptom onset What do these findings mean? – Ag-RDTs detect the vast majority of cases within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease – Out of all assessed tests, the Lumira Dx showed the highest accuracy. The Standard Q wasthe best performing test when only considering those that don’t require an instrument – A standardization of reporting methods for clinical accuracy studies would enhance future test-comparisons
Open AccessThe accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis
Background: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are increasingly being integrated in testing strategies around the world. Studies of the Ag-RDTs have shown variable performance. In this systematic review and meta-analysis, we assessed the clinical accuracy (sensitivity and specificity) of commercially available Ag-RDTs. Methods and Results: We registered the review on PROSPERO (Registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix and bioRvix, FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until April 30 th , 2021. Descriptive analyses of all studies were performed and when more than four studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcriptase polymerase chain reaction testing. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS 2 assessment tool. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy data sets with 112,323 samples. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity was 71.2% (95% confidence interval [CI] 68.2 to 74.0) and increased to 76.3% (CI 73.1 to 79.2) if analysis was restricted to studies that followed the Ag-RDT manufacturers’ instructions. The LumiraDx showed the highest sensitivity with 88.2% (CI 59.0 to 97.5). Of instrument-free Ag-RDTs, Standard Q nasal performed best with 80.2% sensitivity (CI 70.3 to 87.4). Across all Ag-RDTs sensitivity was markedly better on samples with lower Ct-values, i.e., th , 2021, we conducted a systematic review and meta-analysis, including a total of 133 clinical and analytical accuracy studies – Across all meta-analyzed studies, when Ag-RDTs were performed according to manufacturers’ recommendations, they showed a sensitivity of 76.3% (CI 73.1 to 79.2), with the LumiraDx (sensitivity 88.2%, CI 59.0 to 97.5) and of the instrument-free Ag-RDT Standard Q (74.9% sensitivity, CI 69.3 to 79.7) performing best. – Across all Ag-RDTs, sensitivity increased to 95.8% (CI 92.3 to 97.8) when restricting the analysis to samples with high viral loads (i.e., a Ct-value <25) and to 83.8% (CI 76.3 to 89.2) when tests were performed on patients within the first week after symptom onset What do these findings mean? – Ag-RDTs detect the vast majority of cases within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease – Out of all assessed tests, the Lumira Dx showed the highest accuracy. The Standard Q wasthe best performing test when only considering those that don’t require an instrument – A standardization of reporting methods for clinical accuracy studies would enhance future test-comparisons